BioSpace News Archive

Study to Evaluate ALZ-801 as a Precision Medicine Approach to Early Alzheimer’s Disease in Patients with APOE4/4 Genetic Profile

Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced that a Myomo-trained Orthotic & Prosthetic practice in Australia has received its first insurance authorization to fit a patient with a custom MyoPro device.

DaVita Clinical Research investigating presence of COVID-19 antibodies and genetic contributions to infection severity in patients

Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced that the United States Patent and Trademark Office has granted increased patent protection for the Company’s novel CoPrimer™ technology used in the Company’s COVID-19 test kit and its other molecular diagnostic tests.

CARsgen Therapeutics Co., Ltd. announced that the National Medical Products Administration has cleared its Investigational New Drug application for the first-in-class drug candidate CT041, autologous chimeric antigen receptor T cells for the treatment of claudin18.2-positive solid tumors.

Immunic, Inc. announced dosing of the first healthy volunteer in the company’s phase 1 clinical program of IMU-856, an orally available, small molecule modulator that targets a yet undisclosed protein which serves as a transcriptional regulator of intestinal barrier function.

VITALHUB CORP. (TSXV: VHI) (the “Company” or “VitalHub”), is pleased to announce today that it has acquired all the issued and outstanding shares (the “Acquisition”) of Intouch with Health Inc. (“Intouch”), a UK leader for patient flow management solutions. Through its “Intouch Patient Journey Platform,” Intouch specializes in delivering patient-focused flow management solutions that allow patients to more effectively move throughout a hospital. Int

6-Month Interim Data Indicate EB 613 Has Meaningful and Positive Impact on Lumbar Spine Bone Mineral Density (BMD) in a Dose Dependent Manner

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Ocumension Therapeutics, a China-based ophthalmic pharmaceutical platform company, announced the expansion of their exclusive license agreements for the development and commercialization of YUTIQ® and DEXYCU® in certain Asian markets.

Data published in Antimicrobial Agents and Chemotherapy demonstrate MAT2203 (oral amphotericin B) is well tolerated without the side effects commonly seen with IV amphotericin B